We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release third-quarter 2023 results on Nov 2, before the opening bell.
In the last reported quarter, the company’s earnings beat estimates by 18.60%. It delivered an average earnings surprise of 12.51% in the past four quarters.
Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $972.8 million. The same for earnings is pinned at 48 cents per share.
Factors to Note
DENTSPLY SIRONA’s Technologies & Equipment segment is likely to have witnessed organic growth in the quarter under review. Higher demand for clear aligners is expected to have driven the segment’s sales growth, partially offset by weakness in CAD/CAM. Implant sales in China are likely to have reflected the adverse impact of volume-based procurement (VBP) policy in the country. This resulted in lower price per product, especially high-value products.
Strong retail demand for consumable products might have benefited the Consumable segment’s sales during the to-be-reported quarter.
Foreign currency movement had a negative impact on XRAY’s total revenues during the second quarter. The trend is likely to have continued in the third quarter as well.
On its second-quarter earnings call, XRAY’s management stated that market share gains, regional expansion and new product offerings benefited SureSmile product offering. Improved customer conversion rates and lower customer acquisition costs benefited aligner brand Byte. The trend is likely to have continued in the quarter to be reported.
However, a volatile macroeconomic environment raises uncertainty. Inflationary pressure, coupled with commercial investments and restructuring and remediation costs, is likely to have fueled operating expenses during the soon-to-be-reported quarter, thereby hurting margins. The company is expected to provide an updated view on macro headwinds and business performance on its third-quarter earnings call.
Our proven model predicts an earnings beat for DENTSPLY SIRONA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (49 cents per share) and the Zacks Consensus Estimate (48 cents per share), is +1.04% for DENTSPLY SIRONA. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this reporting cycle.
ShockWave Medical (SWAV - Free Report) has an Earnings ESP of +6.07% and a Zacks Rank of 1 at present.
The stock has gained 0.6% year to date. SWAV’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 81.14%.
Baxter International (BAX - Free Report) has an Earnings ESP of +3.86% and a Zacks Rank of 2 at present.
The stock has lost 36.9% year to date. BAX’s earnings missed estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.44%.
Avanos Medical (AVNS - Free Report) has an Earnings ESP of +3.45% and a Zacks Rank of 3 at present.
The stock has lost 34.2% year to date. AVNS’ earnings missed estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 0.61%.
Image: Bigstock
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release third-quarter 2023 results on Nov 2, before the opening bell.
In the last reported quarter, the company’s earnings beat estimates by 18.60%. It delivered an average earnings surprise of 12.51% in the past four quarters.
Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $972.8 million. The same for earnings is pinned at 48 cents per share.
Factors to Note
DENTSPLY SIRONA’s Technologies & Equipment segment is likely to have witnessed organic growth in the quarter under review. Higher demand for clear aligners is expected to have driven the segment’s sales growth, partially offset by weakness in CAD/CAM. Implant sales in China are likely to have reflected the adverse impact of volume-based procurement (VBP) policy in the country. This resulted in lower price per product, especially high-value products.
Strong retail demand for consumable products might have benefited the Consumable segment’s sales during the to-be-reported quarter.
Foreign currency movement had a negative impact on XRAY’s total revenues during the second quarter. The trend is likely to have continued in the third quarter as well.
On its second-quarter earnings call, XRAY’s management stated that market share gains, regional expansion and new product offerings benefited SureSmile product offering. Improved customer conversion rates and lower customer acquisition costs benefited aligner brand Byte. The trend is likely to have continued in the quarter to be reported.
However, a volatile macroeconomic environment raises uncertainty. Inflationary pressure, coupled with commercial investments and restructuring and remediation costs, is likely to have fueled operating expenses during the soon-to-be-reported quarter, thereby hurting margins. The company is expected to provide an updated view on macro headwinds and business performance on its third-quarter earnings call.
DENTSPLY SIRONA Inc. Price and Consensus
DENTSPLY SIRONA Inc. price-consensus-chart | DENTSPLY SIRONA Inc. Quote
Expected Earnings Beat
Our proven model predicts an earnings beat for DENTSPLY SIRONA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (49 cents per share) and the Zacks Consensus Estimate (48 cents per share), is +1.04% for DENTSPLY SIRONA. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this reporting cycle.
ShockWave Medical (SWAV - Free Report) has an Earnings ESP of +6.07% and a Zacks Rank of 1 at present.
The stock has gained 0.6% year to date. SWAV’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 81.14%.
Baxter International (BAX - Free Report) has an Earnings ESP of +3.86% and a Zacks Rank of 2 at present.
The stock has lost 36.9% year to date. BAX’s earnings missed estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 2.44%.
Avanos Medical (AVNS - Free Report) has an Earnings ESP of +3.45% and a Zacks Rank of 3 at present.
The stock has lost 34.2% year to date. AVNS’ earnings missed estimates in the last reported quarter. It has a trailing four-quarter average negative earnings surprise of 0.61%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.